All Photos(1)

Documents

T3202

Torsemide

Name: Torsemide
Brand: SIGMA

≥98% (HPLC), solid

Synonym(s):

Demadex, N-[[(1-Methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₆H₂₀N₄O₃S

CAS Number:

56211-40-6

Molecular Weight:

348.42

MDL number:

MFCD00866166

UNSPSC Code:

12352200

PubChem Substance ID:

329826741

NACRES:

NA.77

Assay

≥98% (HPLC)

form

solid

solubility

DMSO: soluble 18 mg/mL
H₂O: insoluble

originator

Roche

SMILES string

CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc2cccc(C)c2

InChI

1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)

InChI key

NGBFQHCMQULJNZ-UHFFFAOYSA-N

Gene Information

human ... SLC12A1(6557)

Looking for similar products? Visit Product Comparison Guide

Application

Torsemide has been used as an inhibitor of Na⁺ Cl^- co-transporter in transgenic Arabidopsis thaliana plants¹.

Biochem/physiol Actions

Torsemide functions in the thick ascending limb of the loop of Henle and enhances the excretion of sodium, chloride and water from the luminal side of the cells. Furthermore, torsemide can treat oedematous conditions that are associated with diseases such as liver cirrhosis, kidney disorders and chronic congestive heart failure².

Torsemide is a loop diuretic of the pyridine-sulfonylurea class with antialdosteronergic properties and inhibitor of the Na⁺/K⁺/2Cl^-carrier system.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Torsemide is soluble in DMSO at 18 mg/ml and is insoluble in water.

Pictograms

GHS08,GHS07

Signal Word

Warning

Hazard Statements

H319,H361fd

Precautionary Statements

P201 - P202 - P264 - P280 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Eye Irrit. 2 - Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A9C sensitive Cl⁻-accumulation in A. thaliana root cells during salt stress is controlled by internal and external calcium.

Livia Saleh et al.

Plant signaling & behavior, 8(6), e24259-e24259 (2013-04-23)

The involvement of chloride in salt stress symptoms and salt tolerance mechanisms in plants has been less investigated in the past. Therefore, we studied the salt-induced chloride influx in Arabidopsis expressing the GFP-based anion indicator Clomeleon. High salt concentrations induce

Torasemide. A review of its pharmacological properties and therapeutic potential.

H A Friedel et al.

Drugs, 41(1), 81-103 (1991-01-01)

Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from

[Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension].

D V Preobrazhenskiĭ et al.

Kardiologiia, 51(4), 67-73 (2011-06-01)

Torasemide is a loop diuretic and has been used for the treatment of both acute and chronic congestive heart failure (CHF) and arterial hypertension (AH). Torasemide is similar to other loop diuretics in terms of its mechanism of diuretic action.

Loop diuretic therapy in left ventricular systolic dysfunction: has familiarity bred contempt for a critical but potentially nephrotoxic cardio renal therapy?

Robert J MacFadyen et al.

European journal of heart failure, 12(7), 649-652 (2010-06-26)

A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.

M J Barbanoj et al.

Clinical and experimental pharmacology & physiology, 36(5-6), 469-477 (2009-08-14)

1. The main objective of the present study was to compare the bioavailability/bioequivalence of a new prolonged-release (PR) formulation of torasemide with an immediate-release (IR) formulation. In addition, we assessed the pharmacokinetics of both formulations, as well as the urine

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service